The benefits of using Bcl-3 blocking instead of recently approved CDK4/6 inhibitors are that targeting Bcl-3 will only affect metastatic melanoma cells, while CDK4/6 inhibitors affect all actively dividing cells. This evidence concerns the gene BCL3 and melanoma.